-
Vericel NASDAQ:VCEL Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American rights to NexoBrid®, a registration-stage biological orphan product for debridement of severe thermal burns.
Location: 64 Sidney St, Massachusetts, 02139-4170, US | Website: vcel.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
2.784B
Cash
101.7M
Avg Qtr Burn
N/A
Short % of Float
8.22%
Insider Ownership
0.92%
Institutional Own.
-
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NexoBrid® (anacaulase-bcdb) Details Thermal burns | Approved Quarterly sales | |
MACI® (Matrix-Induced Autologous Chondrocyte Implantation) Details Symptomatic chondral or osteochondral defects of the knee | Approved Quarterly sales | |
MACI® (Matrix-Induced Autologous Chondrocyte Implantation) Details Cartilage defects/injuries | Phase 3 Initiation |